Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 53: EUROPA-Studie - Interaktionsanalyse Abb. 54: EUROPA-Studie - Benefits Abb. 55: EUROPA-Studie - HOPE-Studie Abb. 56: EUROPA-Studie - HOPE-Studie Abb. 57: EUROPA-Studie - HOPE-Studie Aktuelles Bild - Abb. 58: EUROPA-Studie - Ergebnisse Abb. 59: EUROPA-Studie - Benefit Abb. 60: EUROPA-Studie - Ergebnisse
Abbildung 58: EUROPA-Studie - Ergebnisse
As prof. Willem Remme, EUROPA Chairman added: "The EUROPA results are profound. Cardiovascular deaths, myocardial infarction and heart failure were all significantly reduced in patients given treatment based on ACE inhibitor perindopril, in addition to standard optimal therapy including aspirin, statins and ß -blockers". In this largest and longest trial of stable CAD patients, perindopril 8 mg once daily reduced significantly: - CV mortality, non-fatal MI and cardiac arrest by 20 % - CV mortality and non fatal MI by 19 % - Fatal and non fatal MI by 24 % - Heart failure by 39 %
 
EUROPA-Studie - Ergebnisse
Vorheriges Bild Nächstes Bild   


Abbildung 58: EUROPA-Studie - Ergebnisse
As prof. Willem Remme, EUROPA Chairman added: "The EUROPA results are profound. Cardiovascular deaths, myocardial infarction and heart failure were all significantly reduced in patients given treatment based on ACE inhibitor perindopril, in addition to standard optimal therapy including aspirin, statins and ß -blockers". In this largest and longest trial of stable CAD patients, perindopril 8 mg once daily reduced significantly: - CV mortality, non-fatal MI and cardiac arrest by 20 % - CV mortality and non fatal MI by 19 % - Fatal and non fatal MI by 24 % - Heart failure by 39 %
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung